DENOsumab (Xgeva®), monthly







Printed: 13/May/2020

Name: Nationalit Gender/A	-		File #: Civil ID: DOB:	Ht (cm): Wt (Kg): BSA (m²):
	☐ Bone r	calcemia of malignancy. netastasis. Cell tumor.		
Central line: ☐ Available ☐ NA			Allergies: ☐ NKA ☐ Yes, specify;	
		ental clearance. CrCl > 45 r	nl/min	
Standard	Protocol:			
DRUG		DOSE	ADMINISTRATION	DAYS
DENOsumab (Xgeva®)) 120 mg	Subcutaneous injection D1	
To be re	peated every	4 weeks until intolerable	toxicity.	
Special in			ep the ampule in room tempera ot warm by any other method.	ture in its original container
Treatmen	t Description:			
Cycle	Date	Xgeva®	Physician	Consultant
C#				
	ed grade 3/4 to Did it indicate Did it indicate	oxicities: ☐ None ☐ H e hospitalization? e chemo-delay for ≥ 7 days' e dose reduction?	ematological ☐ Non-Hemato ☐ Yes ☐ No ? ☐ Yes ☐ No ☐ Yes ☐ No	blogical

Did it indicate G-CSF support?

☐ No

☐ Yes